Candriam S.c.a.’s Eli Lilly & Co Position
Does Candriam S.c.a. own Eli Lilly & Co (LLY)? Yes — 446.3K shares worth $480M (+2.39% of its 13F portfolio) as of Q1 2026, down from 447.0K shares the prior filed quarter.
Position Value
$480M
Q1 2026
Shares
446.3K
% of Portfolio
+2.39%
Quarters Held
30
currently held
Position History LLY
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 446.3K | $480M | +2.39% |
| Q4 2025 | 447.0K | $480M | +2.39% |
| Q3 2025 | 460.1K | $351M | +1.84% |
| Q2 2025 | 460.8K | $359M | +2.07% |
| Q1 2025 | 480.9K | $397M | +2.49% |
| Q4 2024 | 524.2K | $405M | +2.33% |
| Q3 2024 | 505.9K | $448M | +2.58% |
| Q2 2024 | 485.6K | $440M | +2.66% |
| Q1 2024 | 410.5K | $319M | +2.04% |
| Q4 2023 | 377.5K | $220M | +1.52% |
| Q3 2023 | 316.1K | $170M | +1.20% |
| Q2 2023 | 339.3K | $159M | +1.15% |
| Q1 2023 | 484.4K | $153M | +1.06% |
| Q4 2022 | 537.9K | $197M | +1.33% |
| Q3 2022 | 549.0K | $178M | +1.25% |
| Q2 2022 | 480.7K | $156M | +1.28% |
| Q1 2022 | 590.5K | $169M | +1.15% |
| Q4 2021 | 522.2K | $144M | +0.92% |
| Q3 2021 | 137.5K | $32M | +0.22% |
| Q2 2021 | 121.8K | $28M | +0.19% |
| Q1 2021 | 200.7K | $33M | +0.27% |
| Q4 2020 | 200.7K | $34M | +0.27% |
| Q3 2020 | 250.8K | $37M | +0.35% |
| Q2 2020 | 290.0K | $48M | +0.50% |
| Q1 2020 | 298.8K | $38M | +0.43% |
| Q4 2019 | 298.8K | $39M | +0.42% |
| Q3 2019 | 270.3K | $30,000 | +0.38% |
| Q2 2019 | 183.1K | $20M | +0.25% |
| Q1 2019 | 181.0K | $23M | +0.30% |
| Q4 2018 | 147.7K | $17M | +0.26% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Candriam S.c.a.’s full portfolio or all institutional holders of LLY.